# US 2016/0257754 A1 · Sialylated glycoproteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257754 A1
- Document ID: US20160257754A1
- Status: Published application
- Kind: A1
- Application number: 15/028,917
- Filed: 2014-10-14
- Published: 2016-09-08
- Earliest claimed: 2013-10-16
- Assignees: Momenta Pharmaceuticals, Inc.
- Applicants: Momenta Pharmaceuticals, Inc.
- Inventors: Birgit C. SCHULTES; Chia Lin CHU; Laura RUTITZKY; Lynn ZHANG; Leona E. LING
- Web page: https://patentgrep.com/patent/US20160257754A1

## CPC

- C07K 16/2848: {against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61}
- A61K 39/39516: {from serum, plasma}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/06: from serum
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Pharmaceutical preparations containing polypeptides having particular sialylation patterns, and methods for the treatment of immune-related thrombocytopenia with such preparations, are described.

## Claims

### Claim 1

A pharmaceutical preparation formulated for subcutaneous administration, said preparation comprising polypeptides comprising an Fc region, wherein at least 50% of branched glycans on the Fc region are di-sialylated by way of NeuAc-α 2,6-Gal terminal linkages.

### Claim 2 (depends on 1)

The pharmaceutical preparation of claim 1, wherein said polypeptides are present in said pharmaceutical preparation at a concentration of 50-250 mg/mL.

### Claim 3 (depends on 1)

The pharmaceutical preparation of claim 1, wherein less than 50% of branched glycans on the Fc region are mono-sialylated on the α 1,3 arm by way of a NeuAc-α 2,6-Gal terminal linkage.

### Claim 4 (depends on 1)

The pharmaceutical preparation of claim 1, wherein less than 50% of branched glycans on the Fc region are mono-sialylated on the α 1,6 arm by way of a NeuAc-α 2,6-Gal terminal linkage.

### Claim 5

A pharmaceutical preparation comprising polypeptides having an Fc region, wherein at least 50% of branched glycans on the Fc region are di-sialylated by way of NeuAc-α 2,6-Gal terminal linkages and less than 50% of branched glycans on the Fc region are mono-sialylated on the α 1,3 arm by way of a NeuAc-α 2,6-Gal terminal linkage.

### Claim 6

A pharmaceutical preparation comprising polypeptides having an Fc region, wherein at least 50% of branched glycans on the Fc region are di-sialylated by way of NeuAc-α 2,6-Gal terminal linkages and less than 50% of branched glycans on the Fc region are mono-sialylated on the α 1,6 arm by way of a NeuAc-α 2,6-Gal terminal linkage.

### Claim 7

A pharmaceutical preparation comprising polypeptides having an Fc region, wherein at least 85% of branched glycans on the Fc region are di-sialylated by way of NeuAc-α 2,6-Gal terminal linkages.

### Claim 8 (depends on 1)

The pharmaceutical preparation of claim 1, wherein said polypeptides consist essentially of an Fc region.

### Claim 9 (depends on 1)

The pharmaceutical preparation of claim 1, wherein said polypeptides further comprise a Fab region, a heterologous polypeptide sequence, or a non-polypeptide moiety.

### Claim 10 (depends on 9)

The pharmaceutical preparation of claim 9, wherein at least 10% of branched glycans on the Fab region or heterologous polypeptide sequence of said polypeptides are mono-sialylated or di-sialylated.

### Claim 11 (depends on 9)

The pharmaceutical preparation of claim 9, wherein less than 80% of branched glycans on the Fab region or heterologous polypeptide sequence of said polypeptides are mono-sialylated or di-sialylated.

### Claim 12 (depends on 1)

The pharmaceutical preparation of claim 1, wherein said polypeptides are recombinant polypeptides.

### Claim 13 (depends on 1)

The pharmaceutical preparation of claim 1, wherein said polypeptides are derived from plasma.

### Claim 14 (depends on 12)

The pharmaceutical preparation of claim 12, wherein said polypeptides are IgG polypeptides or said polypeptides consist essentially of an Fc region derived from IgG polypeptides.

### Claim 15 (depends on 1)

A method of increasing reticulated platelets in a subject in need thereof, comprising administering to the subject a pharmaceutical preparation of claim 1.

### Claim 16 (depends on 1)

A method of producing new platelets in a subject in need thereof, comprising administering to the subject a pharmaceutical preparation of claim 1.

### Claim 17

A method of increasing reticulated platelets or producing new platelets in a subject in need thereof, comprising administering to the subject a pharmaceutical preparation comprising polypeptides comprising an Fc region, wherein at least 85% of branched glycans on the Fc region are di-sialylated by way of NeuAc-α 2,6-Gal terminal linkages.

### Claim 18 (depends on 15)

The method of claim 15, wherein the subject is not being treated with thrombopoietin or a thrombopoietin receptor agonist or the subject did not respond to treatment with thrombopoietin or a thrombopoietin receptor agonist.

### Claim 19 (depends on 15)

The method of claim 15, wherein the subject has immune-related thrombocytopenia.

### Claim 20 (depends on 15)

The method of claim 15, further comprising, before and/or after the administering step, the step of determining the total platelet count and/or the reticulated platelet count in the subject.

### Claim 21 (depends on 20)

The method of claim 20, further comprising, after the determining step, the step of adjusting the dose of the administered pharmaceutical preparation.

### Claim 22 (depends on 13)

The pharmaceutical preparation of claim 13, wherein said polypeptides are IgG polypeptides or said polypeptides consist essentially of an Fc region derived from IgG polypeptides.
